RetinAI

RetinAI Medical AG is a Switzerland-based company that specializes in AI-powered software solutions for ophthalmology. Founded by Carlos Ciller, Stefanos Apostolopoulos, and Sandro De Zanet, the company aims to improve patient outcomes by harmonizing unstructured medical data. Their focus includes enhancing understanding of diseases such as age-related macular degeneration, diabetic retinopathy, and more.

The flagship product, RetinAI Discovery®, is a cloud-based data management platform that is certified as a Class IIa Medical Device in the EU and has received FDA 510(k) clearance in the US. It aggregates and organizes large datasets from various sources, enabling automatic AI analysis for biomarker detection, disease progression tracking, and treatment outcomes. RetinAI also offers tailored versions of Discovery for clinics and life sciences, supporting workflows, research, and clinical trials.

RetinAI collaborates with healthcare professionals, clinics, and pharmaceutical companies, including partnerships with Novartis and the Ryan Initiative for Macular Research. These collaborations focus on optimizing research and treatment efficiencies in ophthalmology.